Literature DB >> 21055618

Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding.

Holger Kubas1, Martin Schäfer, Ulrike Bauder-Wüst, Matthias Eder, Dörte Oltmanns, Uwe Haberkorn, Walter Mier, Michael Eisenhut.   

Abstract

UNLABELLED: Peptides involving the RGD motive (arginine-glycine-aspartic acid) recognize members of the integrin receptor family. Since the receptors are located mainly on the surface of endothelial cells, structural modifications including multimers of c(RGDfE) were recently found to improve the binding avidity for α(v)β(3) integrin significantly. The multivalent RGD peptides exhibited rather loose linkages partly including oligo(ethylene glycol) spacers (EG(n)) with different chain lengths. Therefore, the dependence of multivalent RGD systems with and without EG(n) linkers were investigated on their binding properties to cultured α(v)β(3) integrin-expressing U87MG cells.
METHODS: We synthesized a series of di-, tri- and tetravalent rigid scaffolds (terephthalic acid, trimesic acid and adamantane-1,3,5,7-tetracarboxylic acid) conjugated to c(RGDyK) ligands, which were linked contiguously or separated by the oligo(ethylene glycol) spacers. The inhibition constants of these c(RGDyK) derivatives were determined by competition assays with (125)I-labeled echistatin.
RESULTS: While c(RGDyK) function is a relative weak competitor against [(125)I]echistatin (K(i), 329 ± 18 nM) for α(v)β(3) integrin-expressing U87MG cells, RGD dimers improved the competition potency considerably (K(i), 64 ± 23 nM). This effect was even more pronounced with the RGD trimers (K(i), 40 ± 7 nM) and tetramers (K(i), 26±9 nM). The introduction of EG(n) spacers and the increase of linker lengths proved to be detrimental since more competitors were needed to compete with [(125)I]echistatin. The EG(6) group, for example, reduced the inhibition constants by 29% (dimer), 57% (trimer) and 97% (tetramer).
CONCLUSION: The binding experiments performed with the three forms of multivalent RGD ligands indicate the weakening of competitive potency against [(125)I]echistatin with the introduction of EG(n) spacers. This effect may be related to the decrease of the effective RGD molarity, which becomes most prominent within the tetravalent series.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055618     DOI: 10.1016/j.nucmedbio.2010.06.005

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  13 in total

1.  Comparison of biological properties of 99mTc-labeled cyclic RGD Peptide trimer and dimer useful as SPECT radiotracers for tumor imaging.

Authors:  Zuo-Quan Zhao; Yong Yang; Wei Fang; Shuang Liu
Journal:  Nucl Med Biol       Date:  2016-02-27       Impact factor: 2.408

Review 2.  Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.

Authors:  Shuang Liu
Journal:  Bioconjug Chem       Date:  2015-08-03       Impact factor: 4.774

3.  Heterodimeric RGD-NGR PET Tracer for the Early Detection of Pancreatic Cancer.

Authors:  Lingyi Sun; Yongkang Gai; Zhonghan Li; Huiqiang Li; Jianchun Li; John Muschler; Rui Kang; Daolin Tang; Dexing Zeng
Journal:  Mol Imaging Biol       Date:  2022-02-28       Impact factor: 3.484

4.  Dynamic display of bioactivity through host-guest chemistry.

Authors:  Job Boekhoven; Charles M Rubert Pérez; Shantanu Sur; Amanda Worthy; Samuel I Stupp
Journal:  Angew Chem Int Ed Engl       Date:  2013-09-24       Impact factor: 15.336

5.  A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer.

Authors:  Martin Schäfer; Ulrike Bauder-Wüst; Karin Leotta; Frederic Zoller; Walter Mier; Uwe Haberkorn; Michael Eisenhut; Matthias Eder
Journal:  EJNMMI Res       Date:  2012-06-06       Impact factor: 3.138

6.  Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds.

Authors:  Ethan A Englund; Deyun Wang; Hidetsugu Fujigaki; Hiroyasu Sakai; Christopher M Micklitsch; Rodolfo Ghirlando; Gema Martin-Manso; Michael L Pendrak; David D Roberts; Stewart R Durell; Daniel H Appella
Journal:  Nat Commun       Date:  2012-01-10       Impact factor: 14.919

7.  Theranostic cRGD-BioShuttle Constructs Containing Temozolomide- and Cy7 For NIR-Imaging and Therapy.

Authors:  Manfred Wiessler; Ute Hennrich; Rüdiger Pipkorn; Waldemar Waldeck; Liji Cao; Jörg Peter; Volker Ehemann; Wolfhard Semmler; Twan Lammers; Klaus Braun
Journal:  Theranostics       Date:  2011-12-11       Impact factor: 11.556

8.  Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.

Authors:  Matthias Eder; Oliver Neels; Miriam Müller; Ulrike Bauder-Wüst; Yvonne Remde; Martin Schäfer; Ute Hennrich; Michael Eisenhut; Ali Afshar-Oromieh; Uwe Haberkorn; Klaus Kopka
Journal:  Pharmaceuticals (Basel)       Date:  2014-06-30

9.  Interface Immobilization Chemistry of cRGD-based Peptides Regulates Integrin Mediated Cell Adhesion.

Authors:  Diego Pallarola; Alexander Bochen; Heike Boehm; Florian Rechenmacher; Tariq R Sobahi; Joachim P Spatz; Horst Kessler
Journal:  Adv Funct Mater       Date:  2013-10-16       Impact factor: 18.808

Review 10.  Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging.

Authors:  Jiyun Shi; Fan Wang; Shuang Liu
Journal:  Biophys Rep       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.